Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 September 2021 | Story Lacea Loader | Photo Supplied
Mr David Noko, newly appointed Chairperson of the UFS Council.

During its third scheduled meeting for the year that took place virtually on 17 September 2021, the Council of the University of the Free State (UFS) appointed Mr David Noko as Chairperson for a term of four years, as from 1 October 2021.

Mr Noko, who was Deputy Chairperson of the Council, will take over the Chairpersonship from Dr Willem Louw, whose term will come to an end on 30 September 2021.
 
“On behalf of the Council, I congratulate Mr Noko and wish him all the best during his term of leading the Council of the UFS. With the skills and competence available in the Council, complemented by Prof Francis Petersen, Rector and Vice-Chancellor, and his team, he has access to a formidable group of individuals to support him in the execution of this very important role,” said Dr Louw during the meeting. 
 
“I am humbled and honoured for the opportunity and thank the Council for their confidence and trust in me. Since serving on the Council, I have become an ambassador of the University of the Free State, talking to many stakeholders about the institution and how much it should be supported. I am here to serve and look forward to doing so in a professional and dignified manner, together with everyone on the Council and with the leadership of the university,” said Mr Noko.
 
Mr Noko is well-known and respected internationally as a business leader. He has a National Higher Diploma in Mechanical Engineering from the Technikon Witwatersrand (now the University of Johannesburg), a Management Development Programme (MDP) Certificate from the University of the Witwatersrand, and a Postgraduate Diploma in Company Directorships from the Graduate Institute of Management and Technology. He also completed a master’s degree in Business Administration at the Heriot-Watt University and a Senior Executive Programme at the London Business School.
 
Before retiring from the corporate world in 2019, Mr Noko was the Executive Vice-President of AngloGold Ashanti, where he was responsible for the company’s global Sustainable Development and Government Relations portfolios. His career began at the General Electric Company (GEC) before moving to South African Breweries in 1987, and then to Pepsi-Cola International in 1994, where he gained extensive international exposure and global experience.
 
In 1999, Mr Noko was appointed as Chief Executive Officer (CEO) of Air Chefs (Pty) Ltd in South Africa, before joining De Beers in 2002. In 2006, he was appointed Managing Director and CEO of De Beers Consolidated Mines Limited (DBCM), and in 2010 he founded his own company, CelaCorp (Pty) Ltd. He also founded ESG Advisory (Pty) Ltd, a company providing advisory services to corporates relating to environment, social and governance matters, mostly focusing on mining companies.
 
He is a member of the Institute of Directors SA and served on the boards of Royal Bafokeng Platinum Limited, Harmony Gold (Deputy Chairman), AstraPak Ltd, and PlatiStone Holdings (Chairman). He is currently a board director of African Rainbow Minerals Ltd, Tongaat Hulett Ltd, and Aveng Moolmans (Pty) Ltd.

The Council also thanked Dr Louw for his service and for the impeccable leadership he displayed during the time he served.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept